본문 바로가기(Skip Contents)
ENGLISH
KOREAN
HOME
ABOUT US
Overview
History
Manufacturing facility
Our Company
PRODUCT
ALS (NeuroNata-R®)
Lou Gehrig's disease
PIPELINE
Pipeline
SLE
CA
R&D
Stem Cell Therapy
IR
Stock Information
Disclosures
Finances
Announcement of Settlement
IR Inquiry
PR
Press Report
Notice
Media
Online Inquiry
전체메뉴
전체메뉴
ABOUT US
Overview
History
Manufacturing facility
Our Company
PRODUCT
ALS (NeuroNata-R®)
Lou Gehrig's disease
PIPELINE
Pipeline
SLE
CA
R&D
Stem Cell Therapy
IR
Stock Information
Disclosures
Finances
Announcement of Settlement
IR Inquiry
PR
Press Report
Notice
Media
Online Inquiry
HOME
ENGLISH
KOREAN
ABOUT US
Overview
History
Manufacturing facility
Our Company
PRODUCT
ALS (NeuroNata-R®)
Lou Gehrig's disease
PIPELINE
Pipeline
Target Disease
Lupus
R&D
Stem Cell Therapy
IR
Stock Information
Disclosures
Finances
Announcement of Settlement
IR Inquiry
PR
Press Report
Notice
Media
Online Inquiry
IR
Corestem is a biopharmaceutical company that
researches and commercializes stem cell technology.
Stock Information
Disclosures
Finances
Announcement of Settlement
IR Inquiry
Disclosures
Stock Information
Disclosures
Finances
Announcement of Settlement
IR Inquiry
Disclosures
No.
Presentation Obligator
Date
Pubilc Disclosure
Writer
1
(주)코아스템
2023.11.23
Material Management Information related to Judgment of Investment(Sponsor-Initiated IND Withdrawal)(항아쿠아포린4 항체 양성 시신경척수염 범주질환 환자에서 동종골수유래 중간엽줄기세포(CE211NS21)와 면역억제제의 병용치료 시 안전성 및 유효성을 평가하기 위한 제1/2a상 임상시험계획승인신청(IND) 반려)
CORESTEMCHEMON Inc.
2
(주)코아스템
2023.08.22
Termination of Under-Supervision Issue(반기보고서 미제출 사유 해소)
KOSDAQ STOCK MKT.
3
(주)코아스템
2023.08.22
Change of Market Division
KOSDAQ STOCK MKT.
4
(주)코아스템
2023.08.14
Designation as Under-Supervision Issue(반기보고서 미제출)
KOSDAQ STOCK MKT.
5
(주)코아스템
2023.08.14
Other Management Information(Voluntary Disclosure)(반기보고서 미제출 사유)
CORESTEMCHEMON Inc.
6
(주)코아스템
2023.04.26
Material Management Information related to Judgment of Investment(항아쿠아포린4 항체 양성 시신경척수염 범주질환 환자에서 동종골수유래 중간엽줄기세포(CE211NS21)와 면역억제제의 병용치료 시 안전성 및 유효성을 평가하기 위한 제1/2a상 임상시험계획승인신청(IND))
CORESTEMCHEMON Inc.
7
(주)코아스템
2023.03.31
Outcomes of Annual Meeting of Shareholders
CORESTEMCHEMON Inc.
8
(주)코아스템
2023.03.22
Submission of Audit Report
CORESTEMCHEMON Inc.
9
(주)코아스템
2023.03.06
[Revised]New Facilities Investment, etc.
CORESTEMCHEMON Inc.
10
(주)코아스템
2023.02.27
New Facilities Investment, etc.
CORESTEMCHEMON Inc.
2023.11.23
Material Management Information related to Judgment of Investment(Sponsor-Initiated IND Withdrawal)(항아쿠아포린4 항체 양성 시신경척수염 범주질환 환자에서 동종골수유래 중간엽줄기세포(CE211NS21)와 면역억제제의 병용치료 시 안전성 및 유효성을 평가하기 위한 제1/2a상 임상시험계획승인신청(IND) 반려)
제출인:
CORESTEMCHEMON Inc.
2023.08.22
Termination of Under-Supervision Issue(반기보고서 미제출 사유 해소)
제출인:
KOSDAQ STOCK MKT.
2023.08.22
Change of Market Division
제출인:
KOSDAQ STOCK MKT.
2023.08.14
Designation as Under-Supervision Issue(반기보고서 미제출)
제출인:
KOSDAQ STOCK MKT.
2023.08.14
Other Management Information(Voluntary Disclosure)(반기보고서 미제출 사유)
제출인:
CORESTEMCHEMON Inc.
2023.04.26
Material Management Information related to Judgment of Investment(항아쿠아포린4 항체 양성 시신경척수염 범주질환 환자에서 동종골수유래 중간엽줄기세포(CE211NS21)와 면역억제제의 병용치료 시 안전성 및 유효성을 평가하기 위한 제1/2a상 임상시험계획승인신청(IND))
제출인:
CORESTEMCHEMON Inc.
2023.03.31
Outcomes of Annual Meeting of Shareholders
제출인:
CORESTEMCHEMON Inc.
2023.03.22
Submission of Audit Report
제출인:
CORESTEMCHEMON Inc.
2023.03.06
[Revised]New Facilities Investment, etc.
제출인:
CORESTEMCHEMON Inc.
2023.02.27
New Facilities Investment, etc.
제출인:
CORESTEMCHEMON Inc.
문의하기